Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
- In the 12 months to Nov 19, 2026, insiders of Arrowhead Pharmaceuticals filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 64 open-market sales (about $37.3M, in 19 filings, by 10 people). One Form 4 can list many transactions.
- In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 33 open-market sales (about $12.5M, in 17 filings).
- The largest sale: Christopher Richard Anzalone, Chief Executive Officer, about $6.9M, filed Dec 16, 2025.
Funds and stakes
- Fund 13F filings recorded in the 12 months show 16 new or larger positions and 14 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
- ClinicalTrials.gov shows 10 studys sponsored by the company updated in the period; the latest, "Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauop..." (Phase 2, status recruiting), was updated on Nov 10, 2026, with primary completion listed for 2027-06.
- FINRA short interest for ARWR on the settlement date of Oct 30, 2026 was 11,583,518 shares (+5.7% on the previous report), about 8.54 days of average volume.
- In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Avoro Capital Advisors LLC (increased, 655,556 shares); Siren, L.L.C. (increased, 100,000 shares); the largest that shrank: Bridgewater Associates (sold out); RTW Investments, LP (sold out). A 13F is a quarter-end snapshot with no trade date.
- For fiscal 2025, the company's proxy statement reported total compensation of $9.03M for its principal executive officer, and an average of $2.09M for the other named executive officers.
Company reports, price and press